Diprovocim-1 is a potent agonist of toll-like receptors TLR2 and TLR1 with an EC50 value of 100 pM. Diprovocim-1 was shown to synergize with anti-PD-L1 treatment, inhibiting tumor growth, generating long-term antitumor memory, and curing or prolonging survival of mice engrafted with the murine melanoma B16-OVA.
Proceedings of the National Academy of Sciences of the United States of America, 115(37), E8698-E8706 (2018-08-29)
Successful cancer immunotherapy entails activation of innate immune receptors to promote dendritic cell (DC) maturation, antigen presentation, up-regulation of costimulatory molecules, and cytokine secretion, leading to activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs). Here we screened a synthetic library
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.